Paying ~42× forward for a ~10%-grower — multiple compression if energy-drink volume growth slows
One-line thesis. Monster is a pristine business — 55% gross margin, 25% ROE, zero debt, ~$2B net cash, decades of share gains in energy drinks — but after a +54% twelve-month run it trades at ~42× forward earnings for a company now growing revenue around 10%, so the price already discounts the quality; we rate it Watch and would want a cheaper entry, not a chase.
◆ Synthos call — HoldMNST is a solid business largely reflected at ~$91 — fine to keep, no reason to chase; it gets interesting again below ~$77.
Downside Risk (lower = safer)
5/10 · Moderate
Zero debt, net cash, beta 0.54 — but 47× trailing / 42× FY26E leaves no cushion for a category-growth wobble.
Growth Quality
6/10 · High
~10% fwd revenue / ~13% fwd EPS CAGR, 55% gross margin, 25% ROE — durable but no longer fast.
Exponential Potential
3/10 · Low
Decelerating single-brand compounder at $95B cap; energy-drink TAM is finite. Not a multibagger from here.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 22%/yrTo justify today’s $98, earnings would have to compound roughly 22% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Monster makes energy drinks — the big cans (Monster Energy, Ultra, Reign, Bang) you see in gas-station coolers. It is a genuinely excellent business: it keeps about 55 cents of gross profit on every dollar of sales, carries no debt, and sits on roughly $2 billion of cash. Over the years it has quietly become one of the two giants of the energy-drink aisle (the other being Red Bull).
The catch: the stock is expensive, and it just had a big year (up more than half). At today's price you're paying about 42 dollars for every 1 dollar of next year's expected profit — a rich price for a company whose sales are now growing around 10% a year, not the explosive rates of its early days. So a great company can still be a so-so stock if you overpay.
Our verdict is Watch — admire it, put it on the list, but wait for a better price rather than buying after the run.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle). The company itself is rock-solid (no debt, steady demand, low-swing stock) — but the high price means a small stumble could still hurt the shares.
Growth Quality 6/10 (good, not great). Very profitable and consistent, but growth has cooled from "fast" to "steady."
Exponential Potential 3/10 (low). It's a one-category company already worth ~$95 billion; energy drinks are a finite market, so don't expect it to multiply from here.
The one big worry: you're paying a premium price for ordinary-speed growth. If energy-drink volumes slow even a little, the stock's rich multiple could shrink and the price could fall even if the business is fine.
Honesty note: no outside expert in the Synthos knowledge base covers Monster, so this verdict rests entirely on the numbers and the quant screen — not on any conviction panel.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = MNST · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$97.60
Market cap$95B
P/E trailing4×
P/E FY26E / FY27E43× / 38×
EV / Sales10.6×
EV / EBITDA33.7×
Gross margin55.5%
Net margin23.1%
Dividend yield0.00%
Beta0.542
52-wk range$59 – $98
RSI(14)72
50 / 200-DMA$87 / $78
12-mo return+54% (SPY +21%)
Street target$91 ($77–$103)
Analyst grades23 Buy · 17 Hold · 3 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MNST · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Monster Beverage Corporation (Nasdaq: MNST) is a global energy-drink company headquartered in Corona, California, founded in 1985 as Hansen Natural and renamed Monster Beverage in 2012. It develops, markets, and distributes energy drinks and concentrates, and since 2015 has been ~19–20% owned by, and distributed through, The Coca-Cola Company's global bottler network — a structural advantage that turned a regional brand into a worldwide one. CEO/co-founders Rodney Sacks and Hilton Schlosberg have run the company for decades (Schlosberg is now Vice Chairman & CEO). Fiscal year ends December 31.
Revenue mix (FY2025, from segment filings):
By product: Monster Energy Drinks $7.67B (92.4%) · Strategic Brands $469M (5.7%) · Alcohol Brands $135M (1.6%). This is effectively a single-category, single-flagship company — the Monster Energy family is the whole story, with the Coca-Cola-portfolio "Strategic Brands" (NOS, Full Throttle, Burn, etc.) and a small, struggling craft-alcohol arm as satellites.
By geography: US & Canada $5.07B (61%) · EMEA $1.90B (23%) · Latin America & Caribbean $698M (8%) · Asia Pacific $624M (8%). International is the faster-growing leg — EMEA and APAC together roughly doubled over five years — and remains the primary runway, but the US still dominates and is a mature market.
The strategic questions are (a) how much international white-space is left, (b) whether the alcohol experiment ever earns its keep, and (c) whether pricing/innovation can keep US volumes growing against Red Bull and newer entrants (Celsius, Alani Nu).
2. The expert thesis
There is no expert coverage of Monster Beverage in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0, and the claims file contains no entries. That is stated plainly: the verdict here is fundamentals- and quant-driven, not conviction-driven. We do not manufacture a panel where none exists, and we cite no claim_ids because none exist to cite.
For context only, the sell-side (not part of our KB, not our anchor) rates it a consensus Buy: 1 Strong Buy, 23 Buy, 17 Hold, 3 Sell, with a price-target consensus of $90.58 — which sits below today's $97.60 price, i.e. the average analyst target implies modest downside. FMP's quant letter rating is B (overall score 3/5), dinged specifically on valuation (P/E score 1/5, P/B score 1/5) while scoring full marks on returns (ROE 5/5, ROA 5/5). The quant picture and our own model agree: elite business, unattractive entry price.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Fortress balance sheet (zero debt, net cash ~$2B, net-debt/EBITDA −0.7×) and low beta (0.54) offset a rich 47× trailing / 42× FY26E multiple with no valuation cushion. Defensive category limits fundamental drawdown; the stock risk is de-rating, not default.
Growth Quality
6 · Good
~10% forward revenue CAGR, ~13% forward EPS CAGR, 55% gross margin, 25% ROE, 22% ROIC — high-quality and durable, but growth has decelerated from its 20%+ heyday to steady mid-teens-and-falling.
Exponential Potential
3 · Low-Moderate
Single-category compounder at a $95B cap; energy-drink TAM is finite and US is mature. Growth is decelerating, not accelerating. Room to run is real internationally but bounded — this is not a multibagger from here.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
Case
Key assumptions
Fair value
Bull
International (EMEA/APAC/LatAm) re-accelerates, pricing sticks, alcohol turns; FY27E EPS beats to ~$2.75 (vs $2.59 cons); market keeps paying a premium ~40×.
~$110 (+13%)
Base(our anchor)
Estimates roughly hit — FY26E EPS $2.30, FY27E $2.59; a durable ~10% compounder with 55% GM and no debt earns a still-premium but compressing ~35× FY27 / ~40× FY26.
~$91 (−7%)
Bear
US volumes stall, Celsius/Alani-Nu share pressure bites, category maturity shows; FY27E EPS misses toward ~$2.35 and the multiple de-rates to ~26× as the growth premium fades.
~$64 (−34%)
Synthos fair value = the base case, ~$91 (−7%), with the full $64–$110 span as the honest range. Our base sits essentially on top of the Street's $90.58 consensus — both say the stock is roughly fairly-to-fully valued here, with the asymmetry tilted slightly to the downside after the run. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MNST is a high-quality compounder that is well past its exponential phase:
Forward growth: revenue CAGR FY25→FY30E ~10.0% ($8.29B → $13.34B); EPS CAGR ~12.7% ($1.95 → $3.55) as buybacks and modest margin gains add a few points over revenue.
Acceleration (the 2nd derivative) is flat-to-negative: revenue growth +10.7% (FY25 actual) → +15.4% (FY26E, partly a FX/comparison bounce) → +8.9% → +9.2% → +9.5% → +7.1% (FY27–30E). No inflection ahead — the model shows a steady high-single-digit grower, not an accelerant. Per our flagship philosophy we pick forward next-exponentials over trailing compounders; MNST is firmly on the compounder end.
Room to run: the global energy-drink category is large and still growing (international is genuinely underpenetrated), but it is finite and maturing, and Monster is already a category duopolist. At $95B the room for a multibagger is limited: a 3× implies a ~$285B beverage company, a level only Coca-Cola and a handful of staples reach.
Reinvestment runway: capex is tiny (~1.4% of revenue) and the company is capital-light — a virtue for returns but a tell that there is no large reinvestment engine to compound into; excess cash goes to buybacks, not a growth flywheel.
Exponential Potential: Low-Moderate (3/10). Own MNST, if at all, for defensive ~10–13% earnings compounding and a fortress balance sheet — not for a fast multibagger. A $10B name with these exact margins and an accelerating top line would score 7–8; a decelerating $95B single-category leader scores 3.
Revenue: FY25 $8.29B, +10.7% (FY24 $7.49B, +4.9% on FY23 $7.14B). Steady double-digit-ish top line at scale.
Quarterly trajectory: Q1'25 $1.855B → Q2 $2.112B → Q3 $2.197B → Q4 $2.131B → Q1'26 $2.353B (+26.9% YoY, aided by an easy comp and pricing). Reacceleration in the latest print is real but partly a soft prior-year base.
Margins: gross 55.5% TTM (up from ~54% FY24 as freight/aluminum eased), operating ~29%, net 23.1% TTM. Best-in-class for a beverage company; gross margin recovery has been a multi-quarter tailwind.
Earnings: net income $1.905B FY25, +26.3% vs FY24 $1.509B; EPS $1.95 ($1.94 diluted) vs $1.50. Note the EPS growth outpaces revenue thanks to margin recovery and buybacks shrinking the share count (from ~1.06B in 2021 to ~975M in 2025).
Cash flow: operating CF $2.10B, capex only −$132M, FCF $1.97B FY25 (FCF yield ~2.1%). Highly cash-generative and capital-light.
Balance sheet:zero total debt, cash & ST investments $2.77B, net cash ~$2.09B (net-debt/EBITDA −0.73×). Current ratio 3.3×. A genuine fortress — the safety here is structural.
Capital return:no dividend. Cash returns come entirely through buybacks (a large ~$3.8B repurchase in 2024, smaller in 2025). This is the one clear lever left for per-share growth.
6. Valuation — priced in or room?
There is no way to call MNST cheap: 47× trailing EPS, 10.6× EV/sales, 34× EV/EBITDA, 46× P/FCF, ~11× book. On forward consensus the multiple compresses only slowly because growth is only ~10%: 42× FY26E → 38× FY27E → 33× FY28E → 28× FY30E. The PEG of ~1.3 (trailing) says you're paying a fair-ish price for the growth rate — but that growth rate is pedestrian relative to the multiple, which is the crux of the Watch call. A reverse read: at $97.60 on FY27E $2.59, the market is paying ~38× for a high-single-digit grower — reasonable only if you believe the premium multiple is permanent (defensive quality, no debt) rather than a fading growth artifact. Street targets (context): consensus $90.58, high $103, low $77 — the average target is below the current price, corroborating our fully-valued read. Not a value buy, and — unlike a true compounder-at-full-price — the forward growth isn't fast enough to reliably outrun the multiple. Fully valued.
7. Technicals (from the tech block)
Trend:up. $97.60 sits above the 50-DMA ($87.13) and 200-DMA ($77.60), and the 50 is above the 200 (golden-cross posture). MACD +2.86 (positive).
Location: just −4.1% off the 52-week high ($97.64), +66% off the 52-week low ($58.65) — a leadership name pressed against its highs, with a shallow max drawdown (−4.1% from peak).
Momentum: RSI(14) 72.5 — overbought (>70). This is the clearest technical caution: the stock is stretched and a mean-reversion pullback toward the rising 50-DMA (~$87) is the more attractive entry.
Relative strength: MNST +53.6% 12-mo vs SPY +20.6% and QQQ +30.3%; +34% 3-mo vs SPY +14%, QQQ +22%. Strong, persistent outperformance — the run is why the valuation is now full.
Read: technicals confirm a strong uptrend but flash overbought — consistent with the fundamental verdict that the good news is priced in. No technical reason to chase; a pullback is the setup to watch.
8. Moat & competitive position
Monster's moat is a brand-plus-distribution combination: a top-two global energy-drink brand (with Red Bull) riding The Coca-Cola Company's worldwide bottler network — a distribution reach nearly impossible for a challenger to replicate, and Coke's ~19–20% ownership aligns incentives. Add 55% gross margins, decades of shelf-space dominance in the highest-velocity CPG category, and a capital-light model with 22–25% returns on capital. The threats are real, though: Celsius and Alani Nu (now under PepsiCo/others) have taken meaningful US share in the "better-for-you"/functional segment, private label is creeping, and the US category is maturing. Monster's answer is Ultra/zero-sugar innovation, Reign/Bang in performance energy, and international expansion.
Peer set (market cap) — note these are broad beverage/staples comps, not pure energy-drink rivals: Mondelez $78B, Colgate-Palmolive $76B, Target $59B, Ambev $48B, Coca-Cola Europacific Partners $47B, Diageo $46B, Keurig Dr Pepper $45B, Kroger $36B, Coca-Cola FEMSA $23B, Coca-Cola Consolidated $15B. MNST commands a materially richer multiple than every one of these — justified by its superior growth and margins, but leaving less room for error. (The truest comps, Red Bull (private) and Celsius, aren't in this FMP peer list.)
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — no dividend, cash returned via opportunistic buybacks (a large tender/repurchase in 2024, ~$3.8B; modest repurchase in 2025), funded entirely from FCF with zero leverage. Buyback is the primary per-share-growth lever given the capital-light model. Appropriate at 22% ROIC, though buying back stock at 40×+ earnings is a mediocre use of cash.
Insider activity: the sampled window (2026-05 to 2026-06) shows routine activity — a CEO-of-EMEA sale of 19,000 shares at $90.90, several gifts and estate/trust transfers (J-Other, G-Gift, price $0) by co-founders Schlosberg and Sacks (estate-planning, not open-market selling), and director option exercises (M-Exempt) by Mark Hall. No cluster of alarming discretionary open-market selling; the zero-price transfers are governance housekeeping, not signals.
Management guidance: Sacks/Schlosberg are long-tenured owner-operators with a strong multi-decade record. Gap flagged: no management claims are ingested into the Synthos KB for MNST, and the full earnings-call Q&A is not on our FMP plan — we can add prepared-remarks guidance via the SEC 8-K and a free transcript source. For now, guidance is not incorporated as a weighted voice.
10. Catalysts & what to watch
Next earnings: 2026-08-06 (Q2'26; Street EPS $0.59, revenue ~$2.42B). Key lines: US energy-drink volume/pricing, gross-margin trajectory (has the recovery peaked?), and international growth.
US category share: scanner data on Monster vs Celsius/Alani Nu/Red Bull — share stabilization or further erosion is the swing factor.
Gross margin: whether the 55%+ level holds or gives back as aluminum/freight normalize.
International ramp: EMEA/APAC/LatAm growth as the primary top-line runway.
Buyback cadence & alcohol: pace of repurchases (the main per-share lever) and any decision on the sub-scale alcohol arm.
Thesis tripwires (what would change the call): two consecutive quarters of US volume decline; gross-margin rollover below ~53%; international growth stalling below high-single digits; or — on the upside — a pullback toward the ~$85–87 50-DMA that resets the entry math (would move us toward a satellite Buy).
11. Key risks
Valuation / de-rating (the primary risk): ~42× forward for a ~10% grower — any growth or margin wobble compresses the multiple, and the shares can fall even if the business is fine. The average sell-side target already sits below the price.
Category maturity & competition: the US energy-drink market is maturing; Celsius, Alani Nu, and Red Bull compete hard, and Monster has ceded share in the functional/better-for-you niche.
Single-category / single-brand concentration: 92% of revenue is one brand family in one category — no diversification cushion if energy drinks stumble (health/regulatory scrutiny of caffeine/energy drinks is a tail risk).
Distribution dependence on Coca-Cola: the Coke bottler relationship is a huge asset but also a dependency; any change in that relationship would be material.
No dividend + buybacks at a high multiple: the only cash-return lever is repurchasing stock at 40×+ earnings — value-destructive if the multiple later compresses.
No expert edge: Synthos has zero KB coverage here, so there is no conviction cushion — the call rests purely on quant/fundamentals.
12. Verdict, position sizing & monitoring
Watch. Monster is an unambiguously excellent business — 55% gross margins, 25% ROE, 22% ROIC, zero debt, ~$2B net cash, a Coca-Cola-powered global distribution moat, and a defensive, cash-generative model. But excellence is not the question; price is. After a +54% twelve-month run the stock trades at ~42× forward earnings for a company now compounding revenue around 10% and decelerating, with an overbought RSI of 72 and a sell-side average target ($90.58) that already sits below the market price. Our base-case fair value of ~$91 (−7%) says the quality is fully in the price. There is no expert conviction in the Synthos KB to override that math.
Sizing:watchlist, no position at this price. If added on a pullback toward the 50-DMA (~$85–87) or a valuation reset toward ~30× forward, we'd size it a defensive satellite (~1–2%), not a core holding — the growth isn't fast enough to be a flagship exponential.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. A meaningful de-rate with intact US volumes would flip this to Buy — Tactical.
Single biggest risk: paying a premium multiple for ordinary-speed growth — multiple compression if energy-drink volume growth slows.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $97.60.
Provenance & disclosures
Traceability: 0 KB claims, breadth 0 — no expert coverage of MNST in the Synthos KB. This note is explicitly fundamentals- and quant-driven; no claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates.
Sell-side context: consensus Buy (1 SB / 23 B / 17 H / 3 S), target $90.58 — shown as context, not as our anchor.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").